| Pack Size/Qty | Price | Unit Price | |
| 90 Rotacap/s | $35.00 | $0.39 | |
| 60 Rotacap/s | $25.50 | $0.43 | |
| 30 Rotacap/s | $15.60 | $0.52 |
Generic Name : Salmeterol and Fluticasone Propionate
Brand Name : Advair Rotacaps
Manufacturer Name : Cipla Ltd - Pharmaceutical Company
Product Code : CRX 281
Delivery Days : 10 to 15 working days
Strength : 500 mg
Packaging : Rotacaps/s
Prescribed For : Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Reaction
Seroflo Rotacaps 50mcg/500mcg is a combination medication designed to provide effective and long-lasting relief for individuals suffering from respiratory conditions, particularly asthma and chronic obstructive pulmonary disease (COPD). This inhalation therapy is a blend of two active ingredients, fluticasone propionate (50mcg) and salmeterol xinafoate (500mcg), each contributing to the management of respiratory symptoms through distinct mechanisms.
Fluticasone propionate (50mcg):
Fluticasone propionate is a corticosteroid with potent anti-inflammatory properties. It works by reducing inflammation and swelling in the airways, thus alleviating symptoms such as wheezing, shortness of breath, and chest tightness. By targeting the underlying inflammation, fluticasone helps to prevent exacerbations and improve overall lung function.
Salmeterol xinafoate (500mcg):
Salmeterol is a long-acting beta2-adrenergic agonist (LABA) that functions as a bronchodilator. It acts on the smooth muscles of the airways, causing relaxation and dilation. This leads to improved airflow and relief from bronchoconstriction, a characteristic feature of asthma and COPD. Salmeterol provides sustained bronchodilation, making it an effective component in preventing and managing respiratory symptoms.
Combining fluticasone and salmeterol in a single Rotacap enhances the overall therapeutic effect, addressing both inflammation and bronchoconstriction to offer comprehensive relief.
Seroflo Rotacaps are designed for inhalation use only and should be administered through a Rotahaler or a similar dry powder inhalation device. The recommended dosage may vary based on the severity of the condition, and it is crucial to follow the prescribing physician's instructions.
Typically, a common starting dose for adults may be one Rotacap (50mcg/500mcg) twice daily. However, individual patient requirements may differ, and adjustments may be made based on the response to treatment and the healthcare provider's assessment.
Patients should be educated on the correct inhalation technique to ensure optimal drug delivery to the lungs. Proper use of the Rotahaler and adherence to the prescribed dosage schedule are essential for achieving the desired therapeutic outcomes.
The efficacy of Seroflo Rotacaps has been extensively studied in clinical trials. Research has demonstrated that the combination of fluticasone propionate and salmeterol provides superior symptom control compared to monotherapy with either component alone. Additionally, the long-acting nature of salmeterol contributes to sustained bronchodilation, reducing the frequency of rescue inhaler use and improving overall quality of life for patients.
The combination therapy has shown efficacy in preventing asthma exacerbations and COPD exacerbations, leading to a reduction in hospitalizations and emergency room visits. These outcomes highlight the significance of Seroflo Rotacaps in managing chronic respiratory conditions effectively.
While Seroflo Rotacaps are generally well-tolerated, it is crucial for patients to be aware of potential side effects. Common side effects may include throat irritation, cough, headache, and oral thrush. Rinsing the mouth with water after inhalation can help minimize the risk of oral thrush.
Serious side effects are rare but may include paradoxical bronchospasm, cardiovascular effects, and systemic corticosteroid effects. Patients should seek medical attention if they experience worsening respiratory symptoms or if they notice any unusual reactions.
It is essential for healthcare providers to assess each patient's medical history, existing conditions, and potential drug interactions before prescribing Seroflo Rotacaps. Regular follow-ups and monitoring can help identify and address any emerging concerns, ensuring the medication's continued safety and efficacy.
Certain patient populations, such as pregnant or breastfeeding women and those with comorbidities, may require special considerations when using Seroflo Rotacaps. The potential benefits and risks should be carefully evaluated in these cases, and alternative treatment options may be explored in consultation with healthcare providers.
Seroflo Rotacaps 50mcg/500mcg represent a well-established and effective combination therapy for the management of asthma and COPD. By combining the anti-inflammatory properties of fluticasone propionate with the sustained bronchodilation provided by salmeterol xinafoate, this medication addresses both components of these chronic respiratory conditions.
Proper patient education, adherence to prescribed dosage, and regular follow-ups with healthcare providers are essential elements of successful long-term management. Seroflo Rotacaps play a significant role in improving the quality of life for individuals suffering from asthma and COPD, offering a comprehensive and synergistic approach to respiratory symptom control.
